A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2017
At a glance
- Drugs GZ 402668 (Primary) ; Aciclovir
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Sanofi
- 17 Jan 2017 Status changed from not yet recruiting to recruiting.
- 10 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 10 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.